Supplier sign in
Home
STAY INFORMED
Subscribe to our monthly newsletter.
Your email address will never be disclosed to any third party.
Read our privacy notice.

     

Industry news
22-02-2021  |  48x
Share this item

Microecology and Pharma Solutions to Speed up Drug Discovery Process

CD Genomics Upgrades Microecology and Pharma Solutions for Speeding up Drug Discovery Process

CD Genomics is a genomics service company with a good reputation for providing reliable microbial sampling products, microbial testing services, microbial genomics services, and integrated bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics recently upgraded its microecology and pharma solutions.

Empowered by leading technology and years of experience in biomedical science, CD Genomics Microbioseq division upgrades an optimized microecology and pharma solutions to support a drug`s journey from discovery to market. Microecology and pharmaceutical solutions can accelerate the research in drug target discovery, microbial therapy and microbial biomarker discovery.

On the one hand, antibiotic resistance has become a major threat to modern medicine. Microbial genomics is a promising method to develop new antibiotics with new drug targets. Meanwhile, certain types of microorganisms can synthesize biologically active molecules and use them as therapeutic agents. The potential of microbial therapy has been demonstrated in probiotics and live bacteria preventive vaccines, and in more recent cases where fecal microbiota transplantation is used to improve human health or cure certain diseases. The benefits of microbial therapy may include preventing infections, eliminating tumors and treating metabolic abnormalities.

CD Genomics offers a full list of microbial genomics services to accelerate the development of microbial therapeutics, including microbial whole genome sequencing, 16S/18S/ITS sequencing, metagenomics, metatranscriptomics, microbial epigenomics, as well as microbial ID and AMR profiling.

Symbiotic microorganisms related to humans or animals play a vital role in shaping host immunity and preventing infectious diseases. In view of the widespread existence of antimicrobial resistance, the promotion of healthy microbiota in humans and animals has become a global problem. Biomarker discovery is one of the most powerful and widely used methods for translating molecular and genomic data into clinical practice. CD Genomics provides (full-length) 16S/18S/ITS sequencing and metagenomics for rapid detection of bacteria, archaea, fungi, and viruses, and a more comprehensive combination of microbial genomics services for further characterization of microbes, genes, or pathways of interest.

We provide next-generation sequencing technology, third-generation sequencing, gene chip analysis, SNP genotyping and real-time qPCR technology to determinate which microorganisms are present in the sample and their quantity, and study the diversity of microorganism and the relationship between the human microbiome and human health. In addition, we can also help you with routine monitoring to control the manufacturing process. Our microbial genomics service is dedicated to supporting the entire process from drug discovery to marketing. said the marketing supervisor of CD Genomics.

About MicrobioSeq Divison of CD Genomics

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. Through years of efforts, CD Genomics has been an internationally leading provider of microbial sampling products, microbial testing services, microbial genomics services, and integrated bioinformatics services for hospitals, food, diagnostics, pharma, agriculture, biotechnology, and research institutes.

Company information

MAXUS MEDIA
LABinsights.net LABinsights.de LABinsights.nl
SIGN UP FOR OUR NEWSLETTER
Newsletter archive
Service and contact
ContactDisclaimerPrivacyAdvertising